Immuron (ASX: IMC) and partner Paladin Labs Inc (TSE: PLB) have made some major steps forward in Canada for the commercialisation of the travellers' diarrhea product known as Travelan®.
Paladin has filed a Non‐Traditional Product Licence Application that has been accepted for review by Health Canada for Travelan®, as an over-the-counter product.
The product is a unique oral preventative against bacteria, with clinical studies showing that the product provides protection against the main cause of traveller’s diarrhea in 90% of consumers who use it.
Paladin obtained the exclusive rights to market and sell Travelan in Canada, Latin America and Sub‐Saharan Africa from Immuron in November 2011. Up to 50% of people who travel to developing countries will contract the disease.
According to the Public Health Agency of Canada, travellers’ diarrhea is the most common illness that affects travellers, especially those travelling to areas such as Central and South America, Mexico, Africa, the Middle East and Asia.
Highlighting the globalisation of Travelan®, the product is currently approved in Australia, New Zealand and South Africa, with the potential global market being identified as US$650 million annually.
Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.